HOME > COMMENTARY
COMMENTARY
-
Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
-
Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
-
Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
-
Change of Tide in Reform: Lopsided Cost Cuts to Balanced Pro-Innovation Policy
December 27, 2023
-
Key Figures in Next Drug Pricing Reform Now All in Place, In What Direction Will They Go for Pro-Innovation Drive?
November 15, 2023
-
Predicting Clinical, Financial Impact of Hemophilia Gene Therapy in Japan
November 7, 2023
-
Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing
October 31, 2023
-
With 2nd Strategy Penned, Can Japan Play Catch-Up with US & Europe in SaMD Push?
October 3, 2023
-
Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
-
Chuikyo Embracing Industry Opinions in Early Phase of Drug Pricing Debate
August 29, 2023
-
Can “G1” Withdrawal Scheme Be Improved Enough to Serve Its Purpose?
August 23, 2023
-
Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
August 7, 2023
-
Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
-
Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
-
Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
-
Will Bill to Amend Medical Infrastructure Law Accelerate Drug Discovery for Rare Diseases?
April 28, 2023
-
Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
-
Revision of Guidelines on Drone Drug Deliveries Expected by March-End: Will Powerful Meds Be OK'ed?
March 17, 2023
-
FY2024 Pricing Reform Likely to Focus on “Balance” between Rewarding Innovation and Optimizing LLP Prices
February 6, 2023
-
LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…